Regeneron Pharmaceuticals, Inc. has declared the receipt of Complete Response Letters from the U.S. Food and Drug Administration concerning their submitted Biologics License Application for the drug odronextamab.
Nystatin, a minuscule molecule drug with a penchant for functioning as an ergosterol binder, engages in targeting fungal cells, blocking their growth and replication.
Ferrer and Verge Genomics have entered into a collaboration to jointly advance the experimental treatment for ALS, designated as VRG50635, into clinical trials.